FDA staff say that Novo Nordisk's (NVO -3.4%) ultra long-acting insulin degludec appears to...

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor

FDA staff say that Novo Nordisk's (NVO -3.4%) ultra long-acting insulin degludec appears to increase the risk of cardiovascular death, and non-fatal heart attacks, strokes and unstable angina by 30% relative to comparators, although the statistical uncertainty is large. An FDA advisory panel is due to vote on Thursday on whether to recommend the drug.